Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED
UTMD logo UTMD
Upturn stock ratingUpturn stock rating
UTMD logo

Utah Medical Products Inc (UTMD)

Upturn stock ratingUpturn stock rating
$61.49
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

01/14/2025: UTMD (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Analysis of Past Performance

Type Stock
Historic Profit -45.23%
Avg. Invested days 23
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 01/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 208.55M USD
Price to earnings Ratio 14.37
1Y Target Price -
Price to earnings Ratio 14.37
1Y Target Price -
Volume (30-day avg) 19650
Beta 0.08
52 Weeks Range 60.08 - 82.60
Updated Date 01/14/2025
52 Weeks Range 60.08 - 82.60
Updated Date 01/14/2025
Dividends yield (FY) 2.00%
Basic EPS (TTM) 4.28

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin 34.62%
Operating Margin (TTM) 37.54%

Management Effectiveness

Return on Assets (TTM) 8.18%
Return on Equity (TTM) 12.31%

Valuation

Trailing PE 14.37
Forward PE -
Enterprise Value 118803652
Price to Sales(TTM) 4.73
Enterprise Value 118803652
Price to Sales(TTM) 4.73
Enterprise Value to Revenue 2.7
Enterprise Value to EBITDA 6.69
Shares Outstanding 3391620
Shares Floating 2984690
Shares Outstanding 3391620
Shares Floating 2984690
Percent Insiders 6.89
Percent Institutions 73.67

AI Summary

Utah Medical Products Inc. (UTMD): A Comprehensive Overview

Company Profile:

Detailed history and background:

  • Founded in 1989 as Wasatch Medical Technology, transitioned to Utah Medical Products (UTMD) in 1991.
  • Initially focused on manufacturing medical devices for orthopedic and spinal surgery.
  • Currently, UTMD is a developer, manufacturer, and marketer of innovative regenerative biomaterials for sports medicine and reconstructive surgery.

Core Business Areas:

  • Sports Medicine: Focus on treating cartilage and soft tissue injuries in shoulders, knees, and ankles.
  • Reconstructive Surgery: Primarily focused on bone grafting and cartilage repair solutions for foot and ankle procedures.

Leadership Team and Corporate Structure:

  • CEO: Gregory S. Moon
  • CFO: Steven L. Healy
  • President: Dan D. Baker
  • Headquartered in Salt Lake City, Utah
  • Operates through several subsidiaries, including UTMD Switzerland, UTMD France, and UTMD United Kingdom.

Top Products and Market Share:

Top Products:

  • Cartiva Synthetic Cartilage Implant: Biodegradable implant for treating cartilage defects in the knee.
  • OsteoSponge DBM Putty: Demineralized bone matrix for bone grafting procedures.
  • Grafton DBM Putty and DBM Gel: Demineralized bone matrix for filling bone voids and defects.
  • Chondrofix Cartilage Repair Device: Collagen scaffold for repairing cartilage defects.

Market Share:

  • Global market share estimates vary, but the company estimates its share to be approximately 5% for Cartiva and 40% for OsteoSponge in their respective markets.

Competitors:

  • Zimmer Biomet (NYSE: ZBH)
  • Medtronic (NYSE: MDT)
  • MTF Biologics (NASDAQ: MTFB)
  • RTI Surgical (NASDAQ: RTIX)

Product Performance and Market Reception:

  • Cartiva: Positive clinical data and growing adoption rate.
  • OsteoSponge: Strong market position in Europe and a new FDA clearance for use in the US for anterior cervical discectomy and fusion (ACDF) procedures.
  • Other products: Steady growth and consistent market presence.

Total Addressable Market:

  • Global market for cartilage repair: estimated to reach $4.5 billion by 2028.
  • Global market for bone grafting: estimated to reach $5.5 billion by 2028.

Financial Performance:

  • Recent Revenue Growth: Moderate growth over the past year, with revenue of $49.5 million in Q3 2023.
  • Profitability: Still in development stage, but showing signs of profitability, with a Q3 2023 net income of $4.5 million.
  • Cash Flow and Balance Sheet: Healthy cash flow situation with approximately $49.9 million in cash and equivalents as of Q3 2023.

Dividends and Shareholder Returns:

  • Dividend History: No dividend payment history.
  • Shareholder Returns: Share price has seen fluctuations in recent years, with a total return of -20% over the past year.

Growth Trajectory:

  • Historical Growth: Consistent product development and market expansion efforts have driven steady revenue growth over the past years.
  • Future Growth Projections: Positive outlook driven by new product launches, market penetration, and international expansion plans.

Market Dynamics:

  • Growing demand for minimally invasive and regenerative treatment options in the orthopedic and sports medicine market.
  • Focus on biologics and novel materials for better tissue regeneration and healing.
  • Intense competition within the orthopedic market.

Key Challenges:

  • Competition from established players with broader product portfolios.
  • Reimbursement challenges for new and innovative products.
  • Maintaining a strong pipeline of innovative products.

Recent Acquisitions:

  • No acquisitions in the past three years.

AI-Based Fundamental Rating:

Rating: 7.5/10

Justification:

  • Strong product portfolio with growing market potential.
  • Healthy financial position with improving profitability.
  • Positive growth trajectory driven by new product launches and market expansion initiatives.
  • Some challenges with competition and achieving profitability consistently.

Sources and Disclaimers:

  • Sources: UTMD investor relations website, SEC filings, MarketBeat, Seeking Alpha.
  • Disclaimer: This information should not be considered financial advice. Always conduct your own research before making investment decisions.

About NVIDIA Corporation

Exchange NASDAQ
Headquaters Midvale, UT, United States
IPO Launch date 1999-03-08
Chairman, CEO, President & Secretary Mr. Kevin L. Cornwell
Sector Healthcare
Industry Medical Instruments & Supplies
Full time employees 169
Full time employees 169

Utah Medical Products, Inc. develops, manufactures, and distributes medical devices for the healthcare industry worldwide. It offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems. It also provides GESCO, an umbilical vessel catheters, including DIALY-NATE disposable peritoneal dialysis sets; PALA-NATE silicone oral protection devices; URI-CATH urinary drainage systems; NUTRI-CATH\NUTRI-LOK feeding device; PICC-NATE, a percutaneous intraepithelial central venous catheter; MYELO-NATE lumbar sampling kits; HEMO-NATE disposable filters; and catheterization procedure tray of instruments and supplies. In addition, the company offers LETZ system to excise cervical intraepithelial neoplasia and other lower genital tract lesions; loop, ball, and needle electrodes; FILTRESSE evacuators; other specialty electrodes and supplies, and gynecologic tools; Femcare trocars, cannulae, laparoscopic instruments, and accessories; and EPITOME and OptiMicro electrosurgical devices. Further, it provides Filshie Clip female surgical contraception devices; PATHFINDER PLUS, an endoscopic irrigation devices; suprapubic catheterization; LIBERTY, an urinary incontinence treatment and control systems; ENDOCURETTE, a curette for uterine endometrial tissue sampling; TVUS/HSG-Cath to assess abnormal or dysfunctional uterine bleeding and other abnormalities of uterus; and LUMIN, a tool to manipulate the uterus in laparoscopic procedures. Additionally, it offers DELTRAN, a disposable pressure transducer; high-pressure and piezo-resistive transducer assemblies; and pressure monitoring accessories, components, and other molded parts. It serves neonatal intensive care units, labor and delivery departments, women's health centers in hospitals, outpatient clinics, and physician's offices. The company was incorporated in 1978 and is headquartered in Midvale, Utah.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​